
DH
Funder
103 Projects, page 1 of 21
Open Access Mandate for Publications and Research data assignment_turned_in Project2017 - 2023Partners:ECRIN, UNIL, VWS, INRAE, WR +24 partnersECRIN,UNIL,VWS,INRAE,WR,HZI,CEA,SSI,EATRIS,Leiden University,UOXF,Government of Netherlands,EPFZ,LSHTM,FHG,GENIBET,VACCINE FORMULATION INSTITUTE LIMITED,UNISI,LUMC,Instruct,INSTITUTE FOR FOOD AND AGRICULTURE RESEARCH AND TE,EUROPEAN VACCINE INITIATIVE e.V,DH,BPRC,Instituto de Biologia Experimental Tecnológica,EUROPEAN VACCINE INITIATIVE,INTRAVACC,BIOASTER FONDATION DE COOPERATION SCIENTIFIQUE,SVAFunder: European Commission Project Code: 730964Overall Budget: 14,556,700 EURFunder Contribution: 14,556,700 EURTRANSVAC2 is the follow-up project to its successful predecessor project TRANSVAC, the European Network of Vaccine Research and Development funded under FP7. The TRANSVAC2 consortium comprises a comprehensive collection of leading European institutions that propose to further advance with the previous initiative towards the establishment of a fully operational and sustainable European vaccine R&D infrastructure. TRANSVAC2 will support innovation for both prophylactic and therapeutic vaccine development based on a disease-overarching and one-health approach, thereby optimising the knowledge and expertise gained during the development of both human and animal vaccines. This will be achieved by bridging the translational gap in biomedical research, and by supporting cooperation between public vaccine R&D institutions of excellence, related initiatives and networks in Europe, and industrial partners. TRANSVAC2 will complement and integrate with existing European research infrastructures in both the public and private sectors. TRANSVAC2 will function as leverage and innovation catalyst between all stakeholders involved in vaccine R&D in Europe and -by providing integrated and overarching vaccine R&D services- will contribute to the development of effective products to address European and global health challenges, to controlling the burden and spread of infectious diseases, and reinforce the economic assets represented by vaccine developers in Europe. The impact of TRANSVAC2 will be maximised by two external advisory bodies. An independent Scientific & Ethics Advisory Committee will provide recommendations surrounding scientific-technical and ethical issues, whereas the coordination of TRANSVAC2 with other related initiatives and the further promotion of the long-term stability of a European vaccine R&D infrastructure will be supported by a Board of Stakeholders comprising representatives of policy and decision makers, industry associations and European infrastructures.
more_vert assignment_turned_in Project2019 - 2028Partners:Public Health England, DHSC, JAGUAR LAND ROVER LIMITED, ESTECO, Intelligent Imaging Innovations Ltd +56 partnersPublic Health England,DHSC,JAGUAR LAND ROVER LIMITED,ESTECO,Intelligent Imaging Innovations Ltd,Food and Agriculture Organisation,Liverpool School of Tropical Medicine,PHE,Spectra Analytics,Birmingham Women’s and Children’s NHS Foundation Trust,Spectra Analytics,Stowers Institute for Medical Research,Betsi Cadwaladr University Health Board,University of Warwick,UCL,Institute Curie,ESTECO,Thales Aerospace,Betsi Cadwaladr University Health Board,The Francis Crick Institute,Philips Electronics U K Ltd,Philips (United Kingdom),Betsi Cadwaladr University Health Board,DH,Heart of England NHS Foundation Trust,The Francis Crick Institute,Thales Group (UK),TRL,HEFT,Rockefeller University,Birmingham Women’s & Children’s NHS FT,Curie Institute,Internat Agency for Res on Cancer (IARC),FAO (Food & Agricultural Org of the UN),University of Birmingham,Pirbright Institute,The Pirbright Institute,Stowers Institute of Medical Research,Rockefeller University,TATA Motors Engineering Technical Centre,University of Warwick,Birmingham Women's Hospital,TRL Ltd (Transport Research Laboratory),LifeGlimmer GmBH,MRC National Inst for Medical Research,Jaguar Cars,Rockefeller University,Thales Group,PUBLIC HEALTH ENGLAND,University of Birmingham,Department of Health and Social Care,Philips (UK),BBSRC,Int Agency for Research on Cancer,Julia Computing,INSERM,Inserm,Liverpool School of Tropical Medicine,Intelligent Imaging Innovations Ltd,THE PIRBRIGHT INSTITUTE,LifeGlimmer GmBHFunder: UK Research and Innovation Project Code: EP/S022244/1Funder Contribution: 5,143,730 GBPWe propose a new phase of the successful Mathematics for Real-World Systems (MathSys) Centre for Doctoral Training that will address the call priority area "Mathematical and Computational Modelling". Advanced quantitative skills and applied mathematical modelling are critical to address the contemporary challenges arising from biomedicine and health sectors, modern industry and the digital economy. The UK Commission for Employment and Skills as well as Tech City UK have identified that a skills shortage in this domain is one of the key challenges facing the UK technology sector: there is a severe lack of trained researchers with the technical skills and, importantly, the ability to translate these skills into effective solutions in collaboration with end-users. Our proposal addresses this need with a cross-disciplinary, cohort-based training programme that will equip the next generation of researchers with cutting-edge methodological toolkits and the experience of external end-user engagement to address a broad variety of real-world problems in fields ranging from mathematical biology to the high-tech sector. Our MSc training (and continued PhD development) will deliver a core of mathematical techniques relevant to all applied modelling, but will also focus on two cross-cutting methodological themes which we consider key to complex multi-scale systems prediction: modelling across spatial and temporal scales; and hybrid modelling integrating complex data and mechanistic models. These themes pervade many areas of active research and will shape mathematical and computational modelling for the coming decades. A core element of the CDT will be productive and impactful engagement with end-users throughout the teaching and research phases. This has been a distinguishing feature of the MathSys CDT and is further expanded in our new proposal. MSc Research Study Groups provide an ideal opportunity for MSc students to experience working in a collaborative environment and for our end-users to become actively involved. All PhD projects are expected to be co-supervised by an external partner, bringing knowledge, data and experience to the modelling of real-world problems; students will normally be expected to spend 2-4 weeks (or longer) with these end-users to better understand the case-specific challenges and motivate their research. The potential renewal of the MathSys CDT has provided us with the opportunity to expand our portfolio of external partners focusing on research challenges in four application areas: Quantitative biomedical research, (A2) Mathematical epidemiology, (A3) Socio-technical systems and (A4) Advanced modelling and optimization of industrial processes. We will retain the one-year MSc followed by three-year PhD format that has been successfully refined through staff experience and student feedback over more than a decade of previous Warwick doctoral training centres. However, both the training and research components of the programme will be thoroughly updated to reflect the evolving technical landscape of applied research and the changing priorities of end-users. At the same time, we have retained the flexibility that allows co-creation of activities with our end-users and allows us to respond to changes in the national and international research environments on an ongoing yearly basis. Students will share a dedicated space, with a lecture theatre and common area based in one of the UK's leading mathematical departments. The space is physically connected to the new Mathematical Sciences building, at the interface of Mathematics, Statistics and Computer Science, and provides a unique location for our interdisciplinary activities.
more_vert assignment_turned_in Project2010 - 2015Partners:HEALTH PROTECTION AGENCY HPA, IARC, LUMC, Helmholtz Zentrum München, DH +8 partnersHEALTH PROTECTION AGENCY HPA,IARC,LUMC,Helmholtz Zentrum München,DH,SUBI,FSIS URCRM,UF,University of Manchester,UCLan,WHO,ISS,DCSFunder: European Commission Project Code: 249675more_vert Open Access Mandate for Publications assignment_turned_in Project2016 - 2019Partners:Stockholm University, Ayuntamiento de Madrid, IAI, Gendarmerie Nationale, IRSN +26 partnersStockholm University,Ayuntamiento de Madrid,IAI,Gendarmerie Nationale,IRSN,ATRISC,ASB,IFRC-SRU INTERNATIONAL FEDERATIO,EUREKA COMUNICAZIONE TELEMATICA SRL,EUSC,University Federico II of Naples,UNIVERSITE COTE D'AZUR,LDI2 / LDII,ENS DE LYON,AIES,RINICOM,Ministère de l'Intérieur,BAES,LEONARDO,AIRBUS DEFENCE AND SPACE SAS,UCSC,UiA,ASTRI POLSKA,DH,SDIS 2B,UCL,Magen David Adom,Nice Sophia Antipolis University,TEKNOLOGIAN TUTKIMUSKESKUS VTT OY,EU,INPSFunder: European Commission Project Code: 700151Overall Budget: 21,101,700 EURFunder Contribution: 18,811,600 EUREffective EU support to a large external crisis requires new approaches. In response to this challenge and to identified user and market needs from previous projects, Reaching Out proposes an innovative multi-disciplinary approach that will optimize the efforts, address a wide spectrum of users and maximize market innovation success. This approach results in five main objectives: to 1. Develop a Collaborative Framework, with distributed platforms of functional services, 2. Implement a flexible and open “collaborative innovation” process involving users and SMEs, suppliers, operators and research organisations, 3. Develop, upgrade and integrate 78 new connectable and interoperable tools, 4. Conduct 5 large scale demonstrations on the field: o health disaster in Africa (Epidemics in Guinea, with strong social and cultural issues), o natural disaster in a politically complex region and a desert environment (Earthquake in the Jordan Valley, led jointly by Jordan, Israel and Palestine), o three global change disasters in Asia targeted at large evacuation and humanitarian support in Bangladesh (long lasting floods, huge storms and associated epidemics,), EU citizen support and repatriation in Shanghai (floods & storm surge), radiological and industrial disasters impacting EU assets in Taiwan (flash floods, landslides, storm surge and chemical and radiological disasters), supported and co-funded by local authorities, 5. Provide recommendations and evaluations for future legal and policy innovations. The project will be conducted under the supervision of senior end-users. It will be performed with flexible and proven procedures by a balanced consortium of users, industry, innovative SMEs, RTO and academia in the EU and the demonstration regions. The main expected impact is to improve external disaster and crisis management efficiency and cost-benefit and increase the EU visibility whilst enhancing EU industry competitiveness and enlarging the market.
more_vert - SARD,EMEA,UMC,Lareb,Amgen,UCL,Johnson & Johnson (United States),Janssen (Belgium),Bayer Pharma AG,DH,AstraZeneca (Sweden),UMCG,University of Liverpool,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.,EPIDEMICO LTD,SRDC,UCB,NOVARTIS,EURORDIS - EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION,EU,HALMEDFunder: European Commission Project Code: 115632
more_vert
chevron_left - 1
- 2
- 3
- 4
- 5
chevron_right